首页> 美国卫生研究院文献>Advances in Hematology >Evaluation of Ferric and Ferrous Iron Therapies in Women with Iron Deficiency Anaemia
【2h】

Evaluation of Ferric and Ferrous Iron Therapies in Women with Iron Deficiency Anaemia

机译:缺铁性贫血妇女的铁和亚铁疗法的评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Introduction. Different ferric and ferrous iron preparations can be used as oral iron supplements. Our aim was to compare the effects of oral ferric and ferrous iron therapies in women with iron deficiency anaemia. Methods. The present study included 104 women diagnosed with iron deficiency anaemia after evaluation. In the evaluations performed to detect the aetiology underlying the iron deficiency anaemia, it was found and treated. After the detection of the iron deficiency anaemia aetiology and treatment of the underlying aetiology, the ferric group consisted of 30 patients treated with oral ferric protein succinylate tablets (2 × 40 mg elemental iron/day), and the second group consisted of 34 patients treated with oral ferrous glycine sulphate tablets (2 × 40 mg elemental iron/day) for three months. In all patients, the following laboratory evaluations were performed before beginning treatment and after treatment. Results. The mean haemoglobin and haematocrit increases were 0.95 g/dL and 2.62% in the ferric group, while they were 2.25 g/dL and 5.91% in the ferrous group, respectively. A significant difference was found between the groups regarding the increase in haemoglobin and haematocrit values (P < 0.05). Conclusion. Data are submitted on the good tolerability, higher efficacy, and lower cost of the ferrous preparation used in our study.
机译:介绍。不同的铁和亚铁制剂可以用作口服铁补充剂。我们的目的是比较口服铁和亚铁疗法对缺铁性贫血妇女的影响。方法。本研究包括104位经评估后被诊断患有铁缺乏性贫血的妇女。在进行检测以发现缺铁性贫血的病因方面进行的评估中,发现并进行了治疗。在检测到缺铁性贫血病因和基础病因后,铁组包括30例口服琥珀酸铁蛋白(2×40μmg元素铁/天)治疗的患者,第二组包括34例接受治疗的患者口服硫酸甘氨酸亚铁片(2×40μmg元素铁/天),持续三个月。在所有患者中,在开始治疗之前和治疗之后进行以下实验室评估。结果。铁剂组的平均血红蛋白和血细胞比容增加分别为0.95μg/ dL和2.62%,铁质组分别为2.25μg/ dL和5.91%。两组之间血红蛋白和血细胞比容值的增加存在显着差异(P <0.05)。结论。提交的数据表明本研究中使用的铁制剂具有良好的耐受性,较高的疗效和较低的成本。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号